WELL Introduces Next-Gen Physician Co-pilot with HEALWELL AI for Chronic Disease Detection

Friday, May 03, 2024

WELL Health Technologies Corp. and its subsidiary HEALWELL AI (TSX: AIDX) have announced the launch of the second generation of WELL AI Decision Support, or "WAIDS". This upgraded version, introduced just six months after its initial release, now offers advanced chronic disease screening capabilities in addition to its previous focus on rare disease detection.

The enhanced WAIDS now empowers healthcare providers with screening tools for a range of chronic conditions including chronic kidney disease, hypertension, and diabetes.

By categorizing patients into high, medium, or low risk groups, WAIDS assists clinicians in identifying care gaps and provides actionable insights directly at the point of care.

"The addition of chronic disease detection represents a significant advancement for our AI-powered physician support tools. Having personally utilized this tool in my practice, found it immensely valuable. It efficiently scans data and offers insights on key diseases, aiding in risk assessment for patients."

The technology driving WAIDS is developed by HEALWELL AI, known for its pioneering rare disease detection capabilities. This collaboration between WELL and HEALWELL marks a pivotal moment in leveraging data science and innovative technology to revolutionize healthcare.

Highlighted the broader impact of the second-generation WAIDS: "goal with WAIDS is to serve as an indispensable co-pilot for medical professionals. By expanding our capabilities to include chronic disease screening, we aim to enhance doctors' decision-making processes, ensuring they remain at the forefront of patient care."

The importance of addressing chronic diseases is underscored by statistics from a 2023 Statistic's Canada report on the Health of Canadians.

The report revealed that 45.1% of Canadians were living with at least one major chronic disease in 2021, with conditions such as diabetes, chronic obstructive pulmonary disease, heart disease, and chronic kidney disease affecting a significant portion of the population. Moreover, these conditions often coexist, contributing to substantial economic costs estimated at $190 billion annually, including direct healthcare expenses and indirect productivity losses.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024